Coloma Jason V sold $594K of MAZE
Coloma Jason V (Chief Executive Officer) sold 22,638 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.77–$27.12, $0.59M total) across 4 trades over 2026-09-02 to 2026-09-03.
How this was made
The 30-second read
Why it matters
The CEO's sale may prompt short-term traders to sell, but the modest amount limits broader impact.
Market read
Insider sell is a routine disclosure with modest trading relevance.
What to watch
Potential upcoming clinical data or financing events not disclosed.
Background
Form 4 filings disclose insider transactions; investors monitor them for signals.
Ticker impact
CEO Jason V. Coloma sold 22,638 shares for $593,954.87, reducing his stake to 27,362 shares.
Potential modest dip in MAZE price over the next few days.
Sale size is modest (~$0.6M) but involves the CEO; market may view it as a negative signal.
Market effects
Limited impact on biotech sector; similar insider sales are common.
No regional effect beyond the stock.
Not globally relevant.
Counterpoint
The sale could be routine liquidity need, not a lack of confidence.
Key entities
- CompanyMaze Therapeutics, Inc.
Biotech firm developing therapies for rare diseases.
- ExecutiveJason V. Coloma
Chief Executive Officer of Maze Therapeutics.